Index

Handbook of Blood Banking & Transfusion Medicine Gundu HR Rao, Ted Eastlund, Latha Jagannathan

BLOOD BANKING
1:Transfusion Medicine of Today and the Future
- TRANSFUSION MEDICINE AND BLOOD BANKING RESEARCH
- TRANSFUSION MEDICINE/ BLOOD BANK PHYSICIANS
- TRANSFUSION MEDICINE AND BLOOD BANKING WORLDWIDE
- CONCLUSION
2:WHO Initiatives on Safe Blood Programs in the Developing Countries
- ISSUES AND CHALLENGES IN BLOOD SAFETY IN DEVELOPING COUNTRIES
- WHO BLOOD SAFETY PROGRAM
- CONCLUSIONS
3:Organization and Operation of a Regional Blood Transfusion Center in India
- ORGANIZATION OF A REGIONAL BLOOD TRANSFUSION CENTER
- DONOR RECRUITMENT AND BLOOD COLLECTION
- RED CELL SEROLOGY TESTING
  - Quality Control of Blood Group Reagents and Cells
- REDUCING THE RISK OF TRANSFUSION-TRANSMISSIBLE INFECTIONS
- COMPONENT PREPARATION FROM WHOLE-BLOOD DONATIONS
- BLOOD COMPONENT PREPARATION BY APHERESIS
  - Monitoring Apheresis Donor Eligibility
- ISSUE AND TRANSPORTATION OF BLOOD COMPONENTS
- AUTOLOGOUS BLOOD TRANSFUSION
- INFECTION PREVENTION AND DISPOSAL OF BIOHAZARDOUS WASTE
- QUALITY MANAGEMENT PROGRAM
- FINANCIAL SUPPORT ISSUES FOR BLOOD BANKS
- RESEARCH AND DEVELOPMENT
4:Blood Donor Suitability and Donation Complications
- BLOOD DONATIONS IN THE UNITED STATES
- BLOOD DONOR SUITABILITY
- BLOOD DONATION PROCESS
- BLOOD DONATION ADVERSE EVENTS
- CONCLUSIONS
5:Leukoreduction of Blood Components
- LEUKOCYTE REMOVAL
  - Mechanisms, Timing, and Potential Adverse Effects
- FEVER AND RIGORS IN RECIPIENTS AND LEUKOREDUCTION
- HLA ANTIBODIES AND REFRACTORINESS TO PLATELET TRANSFUSION
- PREVENTING CYTOMEGALOVIRUS TRANSMISSION BY LEUKOREDUCTION
  - Infection with a Second-Strain of CMV
  - Reactivation of Latent CMV Infection
- TRANSFUSION ASSOCIATED IMMUNE SUPPRESSION AND LEUKOREDUCTION
- LEUKOREDUCTION AND BACTERIAL CONTAMINATION OF BLOOD COMPONENTS
- LEUKOCYTE REDUCTION AND GRAFT-VERSUS-HOST DISEASE
  - Reperfusion Injury
- SUMMARY AND RECOMMENDATIONS
6:Platelets in Health and Disease
- PLATELET MORPHOLOGY
  - Light Microscopy
- PLATELET ULTRASTRUCTURE
- PLATELET ORIGIN AND DEVELOPMENT
- PLATELET FUNCTION
- NEW ADVANCES IN MEASURING PLATELET FUNCTION
- PLATELET PROCOAGULANT ACTIVITY
- PLATELET MEMBRANE GLYCOPROTEINS
  - Glycoprotein IIb/IIIa (Receptor/CD 41a)
  - Glycoprotein Ib-IX Receptor/CD42
    - P-Selectin (CD 62-P)
- PLATELET DISORDERS
  - Pathophysiological Classification of Thrombocytopenias
- THROMBOCYTOPENIAS
- DISORDERS OF PLATELET FUNCTION
- VON WILLEBRAND'S DISEASE
- PLATELET TRANSFUSION THERAPY
- EVALUATION OF PLATELETS
7:Recent Advances in Platelet Preservation and Testing
- ABSTRACT
- INTRODUCTION
- PLATELET BIOCHEMISTRY AND FUNCTION
  - In Vitro Evaluation of Platelet Biochemistry and Function
- FDA RECOMMENDATIONS AND GUIDELINES FOR EVALUATION OF PLATELET FUNCTION
  - In Vitro Evaluation of Platelet Biochemistry and Function
- PLATELET SURVIVAL IN CIRCULATION
- CLINICAL HEMOSTATIC EFFICACY
- STUDIES ON PLATELET PRESERVATION
- DISCUSSION OF PLATELET PRESERVATION METHODS
  - Device for Monitoring Platelet Function
  - Detection of Platelet Function and Platelet Function Inhibition
- CONCLUSION
8:The HLA System and Transfusion Medicine
- THE HLA SYSTEM
- CLINICAL HLA TESTING
- THE HUMAN MINOR HISTOCOMPATIBILITY ANTIGENS
- THE HLA SYSTEM AND TRANSPLANTATION
- THE HLA SYSTEM IN TRANSFUSION THERAPY
- HLA AND DISEASE ASSOCIATION
- HLA AND PARENTAGE TESTING
- SUMMARY
9:Transfusion-associated Graft-versus-Host Disease
- HISTORY OF TA-GVHD
- CLINICAL MANIFESTATIONS
- GENETIC DOCUMENTATION OF TA-GVHD
- TREATMENT OF TA-GVHD
- IRRADIATION OF BLOOD COMPONENTS AS A PREVENTIVE STEP
- INDICATIONS FOR IRRADIATING CELLULAR BLOOD COMPONENTS
- POSSIBLE ALTERNATIVES TO IRRADIATION
  - Leukocyte Reduction
  - Ultraviolet Pathogen Inactivation Methods
- CONCLUSION
CLINICAL USE OF BLOOD COMPONENTS
10:Blood Component Administration and Initial Management of Transfusion Reactions
- PHYSICIAN'S ORDER AND INFORMED CONSENT
- PATIENT BLOOD SAMPLE COLLECTION AND LABELING
- LABORATORY TESTING
  - Red Cell ABO Typing and Compatibility Testing
- TIMING OF THE PRE-SURGICAL BLOOD GROUP TYPING AND COMPATIBILITY TESTING
- THAWING AND POOLING COMPONENTS
- SPECIAL PROCESSING
- RECOGNITION AND MANAGEMENT OF REACTIONS
  - Auditing Blood Component Transfusions
11:Blood Component Transfusion Guidelines for Transfusing Physicians
- RED BLOOD CELLS
- RBC TRANSFUSION GUIDELINES — ADULTS
- RBC TRANSFUSION GUIDELINES — INFANTS AND CHILDREN
- FROZEN DEGLYCEROLIZED RED CELLS — ADULTS AND CHILDREN
- WASHED RED CELLS — ADULTS AND CHILDREN
- PLATELETS
- PLATELET TRANSFUSION GUIDELINES — ADULTS AND CHILDREN
- WASHED PLATELETS — ADULTS AND CHILDREN
- GUIDELINES FOR PLATELET TRANSFUSION OF MORE THAN ONE DOSE PER DAY
- GUIDELINES FOR PLATELET TRANSFUSIONS IN REFRACTORY PATIENTS (Fig. 11.1)
- FROZEN PLASMA
- PLASMA TRANSFUSION GUIDELINES — ADULTS AND CHILDREN
- CRYOPRECIPITATE-REDUCED (CRYO-POOR) PLASMA
- CRYOPRECIPITATED ANTIHEMOPHILIC FACTOR (CRYOPRECIPITATE)
- CRYOTRANSFUSION GUIDELINES — ADULTS AND CHILDREN
- GRANULOCYTE CONCENTRATES
- GRANULOCYTE CONCENTRATE TRANSFUSION GUIDELINES — ADULTS AND CHILDREN
- LEUKOCYTE-REDUCED BLOOD COMPONENTS
- LEUKOCYTE-REDUCED BLOOD COMPONENT TRANSFUSION GUIDELINES —ADULTS AND CHILDREN
- COMPONENTS WITH REDUCED CMV RISK
- PATIENTS AT PARTICULAR RISK FOR CMV
- IRRADIATED CELLULAR BLOOD COMPONENTS
- GUIDELINES FOR IRRADIATED CELLULAR BLOOD COMPONENTS — ADULTS AND CHILDREN
- COMPATIBILITY TESTING PRIOR TO TRANSFUSION (Tables 11.2 and 11.3)
- SOURCE OF BLOOD FOR TRANSFUSIONS
- TRANSFUSING PHYSICIAN'S RESPONSIBILITY TO REPORT ADVERSE OUTCOMES OF BLOOD COMPONENT TRANSFUSION
- RECOGNITION AND MANAGEMENT OF TRANSFUSION REACTIONS
- MANAGEMENT OF ACUTE HEMOLYTIC TRANSFUSION REACTIONS (HTR)
- REPORTING TRANSFUSION REACTIONS
- RECOGNIZING TRANSFUSION-TRANSMITTED DISEASE
- REPORTING TRANSFUSION-TRANSMITTED INFECTION
- RECOGNIZING TRANSFUSION-ASSOCIATED GRAFT-VS-HOST DISEASE
  - Reporting TA-GVHD
  - Reporting Transfusion-Related Fatalities
- INFORMED CONSENT
- RISKS OF BLOOD TRANSFUSIONS — USA
12:Transfusions in Critically Ill Patients
- PATHOGENESIS OF ANEMIA
  - Impairment of Red Cell Production
  - Enhanced Red Cell Consumption
- OXYGEN DELIVERY REQUIREMENTS
  - Oxygen Demand
  - Critical Oxygen Delivery
- APPROPRIATE TRANSFUSION
  - Mortality
    - Selected Outcomes
  - Special Situations
- SPECIAL TOPICS
  - Stored Red Cells
  - Pediatric Critically Ill
    - Blood Conservation
    - Erythropoietin Administration
- CURRENT TRANSFUSION PRACTICES
13:Blood Transfusion in the Operating Room
- GUIDELINES FOR TRANSFUSION
- SUMMARY
14:Massive Transfusion
- PHYSIOLOGY OF BLOOD LOSS
- STORAGE LESION OF BLOOD COMPONENTS
- IMMUNOSUPPRESSION
- NEW TREATMENTS: FACTOR VIIA
- RED CELL SUBSTITUTES
- INTRAOPERATIVE AUTOLOGOUS TRANSFUSION
- SURVIVAL AFTER A MASSIVE TRANSFUSION
- MASSIVE TRANSFUSION PROTOCOL
- SUMMARY
15:Transfusion Therapy for Hemoglobinopathies
- PRINCIPLES OF BLOOD TRANSFUSION IN SICKLE CELL DISEASE
- PRINCIPLES OF BLOOD TRANSFUSION IN BETA-THALASSEMIA MAJOR
16:Hemorrhagic Disorders in the Surgical Patient
- PHYSIOLOGY OF HEMOSTASIS
- BLEEDING DISORDERS
  - Preoperative and Postoperative Management of a Patient with Hemostatic Defect
- SPECIAL HEMOSTATIC CHALLENGES
- DISSEMINATED INTRAVASCULAR COAGULATION
17:Thrombotic Disorders in the Surgical Patient
- PATHOPHYSIOLOGY OF THROMBOSIS
- POSTSURGICAL VENOUS THROMBOEMBOLISM
- PREVENTION OF VENOUS THROMBOEMBOLISM
- TREATMENT OF VENOUS THROMBOEMBOLISM
- HEPARIN-ASSOCIATED THROMBOCYTOPENIA
18:Plasma Transfusion Therapy
- PRODUCTS, PREPARATION AND STORAGE
- CLINICAL USES
- CONTRAINDICATIONS AND PRECAUTIONS1,6-8
  - Adverse Effects1,6,7,24
- ALTERNATIVES TO PLASMA TRANSFUSION1,7,8
19:Use of Cryoprecipitate
- INDICATIONS FOR USE
- ADMINISTRATION AND DOSAGE
20:Coagulation Therapy in Hemophilia
- EVOLUTION OF COAGULATION FACTOR REPLACEMENT THERAPY
  - Hemophilia A
  - Hemophilia B
- CLINICAL APPLICATION OF COAGULATION FACTOR REPLACEMENT THERAPY
- MANAGEMENT OF PATIENTS WITH INHIBITORS
- FUTURE DIRECTIONS
HEMATOPOIETIC STEM CELL TRANSPLANTATION
21:Hematopoietic Stem Cell Transplantation for Malignant Diseases
- SCIENTIFIC BACKGROUND
- PATIENT ELIGIBILITY
  - Host Factors
  - Disease Factors
- CHEMOTHERAPEUTIC AGENTS FOR DOSE-INTENSIVE STRATEGIES
- TOTAL-BODY IRRADIATION
- HEMATOPOIETIC STEM CELLS
  - Hematopoietic Growth Factors and Cytokines
- RESPONSE AND LONG-TERM OUTCOMES
- FUTURE DIRECTIONS
22:Unrelated Donor Stem Cell Transplantation: The Role of the National Marrow Donor Program
- THE NMDP REGISTRY
- THE HLA SYSTEM
  - Impact of HLA match on Transplant Outcome
- SEARCHING THE NMDP REGISTRY FOR AN UNRELATED DONOR
- SUMMARY
23:Umbilical Cord Blood Banking
- DONOR RECRUITMENT
- OBTAINING CONSENT
- MEDICAL EVALUATION OF THE DONOR
- INFECTIOUS DISEASE SCREENING
- COLLECTION
  - Ex utero Collection Method
  - Liquid Preservation of Cord Blood
- PROCESSING, CRYOPRESERVATION AND STORAGE
- TRANSPORTATION OF CORD BLOOD FOR TRANSPLANTATION
- THAWING AND WASHING OF UMBILICAL CORD BLOOD UNITS
- TRANSFUSION OF CORD BLOOD
  - Side Effects and Adverse Reactions and Premedication
  - Administration of Cord Blood Units
- QUALITY ASSURANCE AND QUALITY CONTROL IN CORD BLOOD BANKING
24:Hematopoietic Stem Cell Processing
- SOURCES OF HEMATOPOIETIC STEM CELLS
  - Bone Marrow
  - Peripheral Blood
    - Umbilical Cord Blood
- PROCESSING METHODS
  - Routine Methods
  - Specialized Methods
- CRYOPRESERVATION
- QUALITY CONTROL TESTING TECHNIQUES
- QUALITY ASSURANCE (QA) AND REGULATORY ISSUES
- ACKNOWLEDGMENT
25:Infusion of Hematopoietic Stem Cells
- HPC CRYOPRESERVATION
- SIDE EFFECTS OF INFUSING CRYOPRESERVED BM/PBPC
  - Patient Premedication
  - Preparing for the Transplant and Thawing of the HPCs
- INFUSION OF HEMATOPOIETIC STEM CELLS
  - Patient Monitoring During and After the Infusion
- SIDE EFFECTS OF NON-CRYOPRESERVED PBPC/BM INFUSION
- PREMEDICATION, INFUSION OF NON-CRYOPRESERVED STEM CELLS AND PATIENT MONITORING
- INFUSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS
  - Patient Identification and Inspection of the Product
- CLINICAL MANAGEMENT OF MICROBIALLY CONTAMINATED HPC PRODUCTS
- REPORTING AND INVESTIGATION OF ADVERSE EVENTS RELATED TO THE INFUSION OF HPC
- CONCLUSION
26:Bone Marrow Transplantation: Procedures and Practices in a Developing Country
- TRANSFUSION SUPPORT FOR THE BONE MARROW HARVEST
- ABO MISMATCHED TRANSPLANTS
  - Major ABO Mismatch
  - Minor ABO Mismatch
- CHOICE OF ABO GROUP OF BLOOD PRODUCTS IN ABO AND RHESUS (D) MISMATCHED BMT
- STEM CELL COLLECTION
- STEM CELL INFUSION
  - Marrow Infusion
  - Complications of Marrow Infusion
- BLOOD PRODUCT SUPPORT FOR THE RECIPIENT
- POST-TRANSPLANT TRANSFUSION SUPPORT

INDEX

TOC
Index

Chapter Notes